|
|
Upfront Briefing
Eli Lilly reloaded off China again, expanding its Abbisko pact to as much as $1.9B in milestones — a discovery-stage bet that's almost all back-end, and one more tick on the China-out licensing tape. Down the quality curve, Sangamo filed Chapter 11 and lined up Lilly and Astellas to pick its platforms off the carcass, while Corxel's oral GLP-1 posted 11.5% to keep the obesity arms race honest. The broad tape? Tech got torched on an AI-infrastructure rout; biotech and defensives shrugged.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,365.5 |
(1.4%) |
7.4% |
| Nasdaq 100 |
29,347.3 |
(3.3%) |
16.4% |
| Russell 2000 |
2,975.5 |
(1.0%) |
18.6% |
| Healthcare (XLV) |
152.2 |
1.4% |
(2.1%) |
| Biotech (XBI) |
147.0 |
0.8% |
21.0% |
| Nasdaq Biotech (NBI) |
6,185.6 |
0.9% |
8.4% |
| Clinical Trials (BBC) |
48.5 |
1.6% |
28.9% |
|
- Healthcare caught a defensive bid as money fled tech — XLV +1.4%, XBI +0.8%, NBI +0.9% — with Merck and J&J among the Dow's few green names; the day's marquee sector deal was Abbisko–Lilly's up-to-$1.9B discovery pact.
- The S&P 500 (1.4%) and Nasdaq 100 (3.3%) broke on an AI-infrastructure selloff — SK Hynix throttling advanced-chip output and rising skepticism on hyperscaler returns torched Micron (~13%), Nvidia (~4%) and AMD (~6%) — while elevated Treasury yields after last week's hawkish dot plot offered no cushion.
- Market data: U.S. cash close Tuesday, 23 June 2026.
The Big 3
|
1
|
Abbisko strikes up-to-$1.9B Lilly discovery pact
|
-
Abbisko (02256.HK) entered a strategic research collaboration and license agreement with Eli Lilly worth up to ~$1.9B in milestones, expanding their 2022 pact to cover discovery and early development across multiple Lilly-selected targets.
-
Why it matters:
Lilly is committing up to ~$1.9B in milestones to put Abbisko's discovery engine to work across multiple undisclosed targets — an expansion of their 2022 small-molecule pact, not a one-off. For Lilly it's cheap early-stage optioning against its own target list; for Abbisko it's a second Lilly validation and a milestone annuity without surrendering a marketed asset. It lands squarely in the China-out licensing wave into big pharma. Risk: discovery-stage means nearly all of that $1.9B is back-end and target-contingent — and as China-sourced BD&L it carries COINS Act overhang if extension to biotech lands.
-
Source:
Reuters
-
More:
BioSpectrum Asia;
PR Newswire
|
|
2
|
Sangamo files Chapter 11, sells assets to Lilly and Astellas
|
-
Sangamo (SGMO) filed for bankruptcy and put substantially all assets up for sale, with Lilly (capsid, zinc-finger and MINT delivery platforms plus prion program ST-506) and Astellas (Fabry gene therapy isaralgagene civaparvovec) lined up as stalking-horse bidders.
-
Why it matters:
A 99%-over-five-years drawdown ends the way these usually do — in Chapter 11, with the platforms sold for parts. Lilly is stalking-horse on the capsid, zinc-finger and MINT delivery tech plus prion program ST-506; Astellas takes the Fabry asset. Read it two ways: gene-therapy equity is still being zeroed, but the underlying delivery IP is worth enough that two Big Pharmas want it — and Lilly keeps bottom-fishing after its recent buying run. Risk: stalking-horse bids are a floor, not a close; the hemophilia, chronic-pain (ST-503) and Treg programs remain unsold, and equity sits behind creditors with little left to recover.
-
Source:
Fierce Biotech
-
More:
Sangamo IR
|
|
3
|
Corxel's oral GLP-1 posts 11.5% in Phase 2, heads to pivotal
|
-
Corxel's oral small-molecule GLP-1 CX11 drove up to 11.5% weight loss at 36 weeks in a 246-patient U.S. Phase 2, met its primary endpoints, and showed a 5% GI-driven discontinuation rate with no hepatic safety signal; a global pivotal Phase 3 is next.
-
Why it matters:
11.5% at 36 weeks with a 5% GI-driven discontinuation rate and no hepatic signal puts CX11 in the competitive band of the oral-GLP-1 chase — between AstraZeneca's elecoglipron (10.5% at 26 weeks) and Structure's aleniglipron (15.3% at 44 weeks), all trailing Lilly and Novo. Corxel licensed ex-China rights from Vincentage in 2024 and now has the Series D to fund a global Phase 3. Watch it as a read-through to the public oral players rather than a direct trade — Corxel is private. Risk: trial durations differ so the rankings are soft, the field is crowded, and Corxel only holds rights outside China.
-
Source:
Fierce Biotech
-
More:
BioSpace
|
Everything Else that broke
- Pfizer's Phase III miss for sigvotatug vedotin in lung cancer renewed questions around the asset's positioning. — BioPharma Dive
- UniXell won FDA IND clearance for UX-DA003, an allogeneic iPSC-derived Parkinson's therapy. — PR
- The FTC challenged the antitrust standard in J&J's biosimilar-linked Momenta patent case. — BioCentury
- BIO's board met U.S. officials on China, underscoring policy's boardroom creep. — Fierce Biotech
Deal Flow
|
BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
- Sangamo signed asset-sale agreements in bankruptcy with Lilly and Astellas as stalking-horse bidders for its delivery platforms and Fabry program (see The Big 3). — Fierce Biotech
- Merck KGaA seeded Versant NewCo Saturnus Bio with $50M for a minority stake, milestone-tied funding and an exclusive option to acquire. — Fierce Biotech
- Abbisko expanded its Lilly tie-up through a strategic research collaboration and license agreement (see The Big 3). — PR
- Coherus and Zumutor started a Phase I combo study pairing ZM008 with LOQTORZI after first-patient dosing. — PR
- Flagship and Lean launched a Saudi research collaboration around healthcare innovation and AI-enabled biomedical research. — PR
VC / Private Financings
- Osanni Bio raised $190M in a Series B to build its ophthalmology and cardiology pipeline and affiliate model; the round was backed by ARCH Venture Partners, GV, and other new and existing investors. — Fierce Biotech
- RQ Bio raised an oversubscribed $115M (£85.5M) Series A led by Frazier Life Sciences, with EQT Life Sciences, Forbion, Monograph and Wellington Management joining founding investor LifeArc Ventures, to push long-acting flu-prevention antibody RQB01 toward the clinic. — GlobeNewswire
IPOs / Follow-Ons
- uniQure priced an upsized $225M follow-on at $45.50 per share, with closing expected June 25. — PR
- MoonLake priced an upsized $200M public offering of shares and pre-funded warrants. — PR
- Serapha Bio is going public via an all-stock reverse merger with Boundless Bio (BOLD), bringing ~$230M and an in vivo base-editing program for alpha-1 antitrypsin deficiency. — Fierce Biotech
|
Big pharma's buying Chinese chemistry by the billion and picking the gene-therapy bargain bin, while the chip trade's on fire. Same circus, new tent.
— BioBucks Team
|
|
|
